Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
|Videos|June 8, 2015
PD-1 Inhibitor Yields Responses in Hepatocellular Carcinoma
Author(s)Anthony B. El-Khoueiry, MD
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
Advertisement
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in gastroesophageal cancer.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.
Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
3
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
4
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
5